| Towards a new combination therapy for tuberculosis with next generation benzothiazinones V Makarov, B Lechartier, M Zhang, J Neres, AM van der Sar, SA Raadsen, ... EMBO molecular medicine 6 (3), 372-383, 2014 | 404 | 2014 |
| Review of therapeutic drug monitoring of anticancer drugs part two–targeted therapies N Widmer, C Bardin, E Chatelut, A Paci, J Beijnen, D Levêque, G Veal, ... European journal of cancer 50 (12), 2020-2036, 2014 | 351 | 2014 |
| Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib A Haouala, N Widmer, MA Duchosal, M Montemurro, T Buclin, ... Blood, The Journal of the American Society of Hematology 117 (8), e75-e87, 2011 | 306 | 2011 |
| Review of therapeutic drug monitoring of anticancer drugs part 1–cytotoxics A Paci, G Veal, C Bardin, D Levêque, N Widmer, J Beijnen, A Astier, ... European journal of cancer 50 (12), 2010-2019, 2014 | 295 | 2014 |
| Therapeutic drug monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry A Haouala, B Zanolari, B Rochat, M Montemurro, K Zaman, MA Duchosal, ... Journal of Chromatography B 877 (22), 1982-1996, 2009 | 239 | 2009 |
| Population pharmacokinetics of imatinib and the role of α1‐acid glycoprotein N Widmer, LA Decosterd, C Csajka, S Leyvraz, MA Duchosal, A Rosselet, ... British journal of clinical pharmacology 62 (1), 97-112, 2006 | 223 | 2006 |
| Benchmarking therapeutic drug monitoring software: a review of available computer tools A Fuchs, C Csajka, Y Thoma, T Buclin, N Widmer Clinical pharmacokinetics 52, 9-22, 2013 | 196 | 2013 |
| Multiplex ultra-performance liquid chromatography-tandem mass spectrometry method for simultaneous quantification in human plasma of fluconazole, itraconazole … LA Decosterd, B Rochat, B Pesse, T Mercier, F Tissot, N Widmer, J Bille, ... Antimicrobial agents and chemotherapy 54 (12), 5303-5315, 2010 | 153 | 2010 |
| Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability N Widmer, LA Decosterd, S Leyvraz, MA Duchosal, A Rosselet, ... British journal of cancer 98 (10), 1633-1640, 2008 | 136 | 2008 |
| Therapeutic drug monitoring in cancer–are we missing a trick? C Bardin, G Veal, A Paci, E Chatelut, A Astier, D Levêque, N Widmer, ... European journal of cancer 50 (12), 2005-2009, 2014 | 134 | 2014 |
| Higher CNS Penetration-Effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid A Cusini, PL Vernazza, S Yerly, LA Decosterd, B Ledergerber, CA Fux, ... JAIDS Journal of Acquired Immune Deficiency Syndromes, 2012 | 126 | 2012 |
| Functional consequence of MDR1 expression on imatinib intracellular concentrations N Widmer, S Colombo, T Buclin, LA Decosterd Blood 102 (3), 1142-1142, 2003 | 115 | 2003 |
| Oral imatinib treatment reduces early fibrogenesis but does not prevent progression in the long term M Neef, M Ledermann, H Saegesser, V Schneider, N Widmer, ... Journal of hepatology 44 (1), 167-175, 2006 | 108 | 2006 |
| Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): an emerging … M von Mehren, N Widmer Cancer treatment reviews 37 (4), 291-299, 2011 | 95 | 2011 |
| The steps to therapeutic drug monitoring: a structured approach illustrated with imatinib T Buclin, Y Thoma, N Widmer, P André, M Guidi, C Csajka, LA Decosterd Frontiers in pharmacology 11, 177, 2020 | 89 | 2020 |
| Determination of imatinib (Gleevec®) in human plasma by solid-phase extraction–liquid chromatography–ultraviolet absorbance detection N Widmer, A Beguin, B Rochat, T Buclin, T Kovacsovics, MA Duchosal, ... Journal of Chromatography B 803 (2), 285-292, 2004 | 86 | 2004 |
| Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: results from a randomized controlled trial V Gotta, N Widmer, LA Decosterd, Y Chalandon, D Heim, M Gregor, ... Cancer chemotherapy and pharmacology 74, 1307-1319, 2014 | 82 | 2014 |
| Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics N Widmer, P Meylan, A Ivanyuk, M Aouri, LA Decosterd, T Buclin Clinical pharmacokinetics 49, 741-765, 2010 | 69 | 2010 |
| Population pharmacokinetic study of gentamicin in a large cohort of premature and term neonates A Fuchs, M Guidi, E Giannoni, D Werner, T Buclin, N Widmer, C Csajka British journal of clinical pharmacology 78 (5), 1090-1101, 2014 | 67 | 2014 |
| Therapeutic drug monitoring of imatinib: Bayesian and alternative methods to predict trough levels V Gotta, N Widmer, M Montemurro, S Leyvraz, A Haouala, LA Decosterd, ... Clinical pharmacokinetics 51, 187-201, 2012 | 64 | 2012 |
Thierry BuclinCHUV and UNIL Lausanne (Switzewrland)在 chuv.hospvd.ch 的电子邮件经过验证
